Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models.

Mitchell LA, Yagiz K, Hofacre A, Viaud S, Munday AW, Espinoza FL, Mendoza D, Rodriguez-Aguirre ME, Bergqvist S, Haghighi A, Miner MV, Accomando WP, Burrascano C, Gammon D, Gruber HE, Jolly DJ, Lin AH.

Oncotarget. 2019 Mar 19;10(23):2252-2269. doi: 10.18632/oncotarget.26785. eCollection 2019 Mar 19.

2.

Exclusivity and Compensation in NFκB Dimer Distributions and IκB Inhibition.

Ramsey KM, Chen W, Marion JD, Bergqvist S, Komives EA.

Biochemistry. 2019 May 28;58(21):2555-2563. doi: 10.1021/acs.biochem.9b00008. Epub 2019 May 14.

PMID:
31033276
3.

Correction to Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.

Kung PP, Rui E, Bergqvist S, Bingham P, Braganza J, Collins M, Cui M, Diehl W, Dinh D, Fan C, Fantin VR, Gukasyan HJ, Hu W, Huang B, Kephart S, Krivacic C, Kumpf RA, Li G, Maegley KA, McAlpine I, Nguyen L, Ninkovic S, Ornelas M, Ryskin M, Scales S, Sutton S, Tatlock J, Verhelle D, Wang F, Wells P, Wythes M, Yamazaki S, Yip B, Yu X, Zehnder L, Zhang WG, Rollins RA, Edwards M.

J Med Chem. 2016 Dec 22;59(24):11196. doi: 10.1021/acs.jmedchem.6b01747. Epub 2016 Dec 12. No abstract available.

PMID:
27936698
4.

Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.

Kung PP, Rui E, Bergqvist S, Bingham P, Braganza J, Collins M, Cui M, Diehl W, Dinh D, Fan C, Fantin VR, Gukasyan HJ, Hu W, Huang B, Kephart S, Krivacic C, Kumpf RA, Li G, Maegley KA, McAlpine I, Nguyen L, Ninkovic S, Ornelas M, Ryskin M, Scales S, Sutton S, Tatlock J, Verhelle D, Wang F, Wells P, Wythes M, Yamazaki S, Yip B, Yu X, Zehnder L, Zhang WG, Rollins RA, Edwards M.

J Med Chem. 2016 Sep 22;59(18):8306-25. doi: 10.1021/acs.jmedchem.6b00515. Epub 2016 Sep 6. Erratum in: J Med Chem. 2016 Dec 22;59(24):11196.

PMID:
27512831
5.

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance.

Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, Bergqvist S, Solowiej J, Diehl W, He YA, Yu X, Nagata A, VanArsdale T, Murray BW.

Mol Cancer Ther. 2016 Oct;15(10):2273-2281. Epub 2016 Aug 5.

6.

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, Timofeevski S, Katayama R, Iafrate AJ, Le L, McTigue M, Getz G, Johnson TW, Engelman JA.

N Engl J Med. 2016 Jan 7;374(1):54-61. doi: 10.1056/NEJMoa1508887. Epub 2015 Dec 23.

7.

Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design.

Chen P, Deng YL, Bergqvist S, Falk MD, Liu W, Timofeevski S, Brooun A.

Protein Sci. 2014 Oct;23(10):1332-40. doi: 10.1002/pro.2517. Epub 2014 Aug 7.

8.

Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance.

Schwartz PA, Kuzmic P, Solowiej J, Bergqvist S, Bolanos B, Almaden C, Nagata A, Ryan K, Feng J, Dalvie D, Kath JC, Xu M, Wani R, Murray BW.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):173-8. doi: 10.1073/pnas.1313733111. Epub 2013 Dec 17.

9.

Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein-protein interaction.

Cardoso R, Love R, Nilsson CL, Bergqvist S, Nowlin D, Yan J, Liu KK, Zhu J, Chen P, Deng YL, Dyson HJ, Greig MJ, Brooun A.

Protein Sci. 2012 Dec;21(12):1885-96. doi: 10.1002/pro.2172. Epub 2012 Nov 9.

10.

ABRF-MIRG benchmark study: molecular interactions in a three-component system.

Yamniuk AP, Edavettal SC, Bergqvist S, Yadav SP, Doyle ML, Calabrese K, Parsons JF, Eisenstein E.

J Biomol Tech. 2012 Sep;23(3):101-14. doi: 10.7171/jbt.12-2303-003.

11.

MIRG Survey 2011: snapshot of rapidly evolving label-free technologies used for characterizing molecular interactions.

Yadav SP, Bergqvist S, Doyle ML, Neubert TA, Yamniuk AP.

J Biomol Tech. 2012 Sep;23(3):94-100. doi: 10.7171/jbt.12-2303-002.

12.

Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting.

van Meeteren LA, Thorikay M, Bergqvist S, Pardali E, Stampino CG, Hu-Lowe D, Goumans MJ, ten Dijke P.

J Biol Chem. 2012 May 25;287(22):18551-61. doi: 10.1074/jbc.M111.338103. Epub 2012 Apr 5.

13.

Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer.

Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, Simmons BH, Wu A, Lee JH, Bergqvist S, Kraynov E.

J Exp Clin Cancer Res. 2012 Mar 23;31:26. doi: 10.1186/1756-9966-31-26.

14.

A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.

Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E.

J Pharmacol Exp Ther. 2012 Jun;341(3):702-8. doi: 10.1124/jpet.112.191999. Epub 2012 Mar 13.

PMID:
22414855
15.

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity.

Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, Bergqvist S, Baxi SM, Rohner A, Shen AC, Huang C, Sokolowski SA, Sharp LL.

Cancer Immunol Immunother. 2012 Oct;61(10):1721-33. Epub 2012 Mar 11.

PMID:
22406983
16.

Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone.

Kung PP, Sinnema PJ, Richardson P, Hickey MJ, Gajiwala KS, Wang F, Huang B, McClellan G, Wang J, Maegley K, Bergqvist S, Mehta PP, Kania R.

Bioorg Med Chem Lett. 2011 Jun 15;21(12):3557-62. doi: 10.1016/j.bmcl.2011.04.130. Epub 2011 May 5.

PMID:
21612924
17.

Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.

Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, Wickman G, Chen JH, Wang J, Jiang X, Amundson K, Simon R, Erbersdobler A, Bergqvist S, Feng Z, Swanson TA, Simmons BH, Lippincott J, Casperson GF, Levin WJ, Stampino CG, Shalinsky DR, Ferrara KW, Fiedler W, Bertolini F.

Cancer Res. 2011 Feb 15;71(4):1362-73. doi: 10.1158/0008-5472.CAN-10-1451. Epub 2011 Jan 6.

18.

Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.

Li G, Zhang L, Chen E, Wang J, Jiang X, Chen JH, Wickman G, Amundson K, Bergqvist S, Zobel J, Buckman D, Baxi SM, Bender SL, Casperson GF, Hu-Lowe DD.

Cancer Res. 2010 Dec 15;70(24):10243-54. doi: 10.1158/0008-5472.CAN-10-1996. Erratum in: Cancer Res. 2011 Feb 15;71(4):1507.

19.

The RelA nuclear localization signal folds upon binding to IκBα.

Cervantes CF, Bergqvist S, Kjaergaard M, Kroon G, Sue SC, Dyson HJ, Komives EA.

J Mol Biol. 2011 Jan 21;405(3):754-64. doi: 10.1016/j.jmb.2010.10.055. Epub 2010 Nov 19.

20.

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.

Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J, Dagostino E, Knighton D, Loi CM, Zager M, Kraynov E, Popoff I, Christensen JG, Martinez R, Kephart SE, Marakovits J, Karlicek S, Bergqvist S, Smeal T.

Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51. doi: 10.1073/pnas.0911863107. Epub 2010 May 3.

21.

Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site.

Himmel DM, Maegley KA, Pauly TA, Bauman JD, Das K, Dharia C, Clark AD Jr, Ryan K, Hickey MJ, Love RA, Hughes SH, Bergqvist S, Arnold E.

Structure. 2009 Dec 9;17(12):1625-1635. doi: 10.1016/j.str.2009.09.016.

22.

Kinetic enhancement of NF-kappaBxDNA dissociation by IkappaBalpha.

Bergqvist S, Alverdi V, Mengel B, Hoffmann A, Ghosh G, Komives EA.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19328-33. doi: 10.1073/pnas.0908797106. Epub 2009 Nov 3.

23.

Characterization of the CHK1 allosteric inhibitor binding site.

Vanderpool D, Johnson TO, Ping C, Bergqvist S, Alton G, Phonephaly S, Rui E, Luo C, Deng YL, Grant S, Quenzer T, Margosiak S, Register J, Brown E, Ermolieff J.

Biochemistry. 2009 Oct 20;48(41):9823-30. doi: 10.1021/bi900258v.

PMID:
19743875
24.

Structural and biophysical characterization of XIAP BIR3 G306E mutant: insights in protein dynamics and application for fragment-based drug design.

Moore CD, Wu H, Bolaños B, Bergqvist S, Brooun A, Pauly T, Nowlin D.

Chem Biol Drug Des. 2009 Sep;74(3):212-23. doi: 10.1111/j.1747-0285.2009.00862.x. Epub 2009 Jul 29.

PMID:
19660030
25.

Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib.

Solowiej J, Bergqvist S, McTigue MA, Marrone T, Quenzer T, Cobbs M, Ryan K, Kania RS, Diehl W, Murray BW.

Biochemistry. 2009 Jul 28;48(29):7019-31. doi: 10.1021/bi900522y.

PMID:
19526984
26.

The IkappaBalpha/NF-kappaB complex has two hot spots, one at either end of the interface.

Bergqvist S, Ghosh G, Komives EA.

Protein Sci. 2008 Dec;17(12):2051-8. doi: 10.1110/ps.037481.108. Epub 2008 Sep 29.

27.

Inhibitor kappaB kinase beta binding by inhibitor kappaB kinase gamma.

Drew D, Shimada E, Huynh K, Bergqvist S, Talwar R, Karin M, Ghosh G.

Biochemistry. 2007 Oct 30;46(43):12482-90. Epub 2007 Oct 9.

PMID:
17924664
28.
29.

Thermodynamics reveal that helix four in the NLS of NF-kappaB p65 anchors IkappaBalpha, forming a very stable complex.

Bergqvist S, Croy CH, Kjaergaard M, Huxford T, Ghosh G, Komives EA.

J Mol Biol. 2006 Jul 7;360(2):421-34. Epub 2006 May 19.

30.

Lactic acid decreases Fe(II) and Fe(III) retention but increases Fe(III) transepithelial transfer by Caco-2 cells.

Bergqvist SW, Sandberg AS, Andlid T, Wessling-Resnick M.

J Agric Food Chem. 2005 Aug 24;53(17):6919-23.

PMID:
16104821
31.

Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases.

Mallbris L, Larsson P, Bergqvist S, Vingård E, Granath F, Ståhle M.

J Invest Dermatol. 2005 Mar;124(3):499-504.

32.

Biophysical characterization of the free IkappaBalpha ankyrin repeat domain in solution.

Croy CH, Bergqvist S, Huxford T, Ghosh G, Komives EA.

Protein Sci. 2004 Jul;13(7):1767-77.

33.

Allosteric changes in solvent accessibility observed in thrombin upon active site occupation.

Croy CH, Koeppe JR, Bergqvist S, Komives EA.

Biochemistry. 2004 May 11;43(18):5246-55.

PMID:
15122890
34.

Heat capacity effects of water molecules and ions at a protein-DNA interface.

Bergqvist S, Williams MA, O'Brien R, Ladbury JE.

J Mol Biol. 2004 Feb 27;336(4):829-42.

PMID:
15095863
35.

Two different proteins that compete for binding to thrombin have opposite kinetic and thermodynamic profiles.

Baerga-Ortiz A, Bergqvist S, Mandell JG, Komives EA.

Protein Sci. 2004 Jan;13(1):166-76.

36.

Halophilic adaptation of protein-DNA interactions.

Bergqvist S, Williams MA, O'Brien R, Ladbury JE.

Biochem Soc Trans. 2003 Jun;31(Pt 3):677-80. Review.

PMID:
12773181
37.

Reversal of halophilicity in a protein-DNA interaction by limited mutation strategy.

Bergqvist S, Williams MA, O'Brien R, Ladbury JE.

Structure. 2002 May;10(5):629-37.

38.

Site-specific cation binding mediates TATA binding protein-DNA interaction from a hyperthermophilic archaeon.

Bergqvist S, O'Brien R, Ladbury JE.

Biochemistry. 2001 Feb 27;40(8):2419-25.

PMID:
11327862
39.

5-(1-propargylamino)-2'-deoxyuridine (UP): a novel thymidine analogue for generating DNA triplexes with increased stability.

Bijapur J, Keppler MD, Bergqvist S, Brown T, Fox KR.

Nucleic Acids Res. 1999 Apr 15;27(8):1802-9.

40.

The contribution of cytosine protonation to the stability of parallel DNA triple helices.

Asensio JL, Lane AN, Dhesi J, Bergqvist S, Brown T.

J Mol Biol. 1998 Feb 6;275(5):811-22.

PMID:
9480771
41.

[Current views on treatment of tuberculosis. Symposium (IV). Bacteriological aspects in chemoresistance].

Bergqvist S, Wasserman J.

Lakartidningen. 1966 May 4;63(18):1749-52. Swedish. No abstract available.

PMID:
5917519
42.

[Pleurisy].

BERGQVIST S.

Sven Lakartidn. 1960 Apr 8;57:1113-36. Swedish. No abstract available.

PMID:
13799437
43.

Bilateral pleurisy in a case of rheumatoid arthritis.

BERGQVIST S.

Acta Rheumatol Scand. 1960;6:76-80. No abstract available.

PMID:
13799435
44.

[Corticotropin-or cortisone-activated pulmonary tuberculosis].

BERGQVIST S.

Sven Lakartidn. 1959 Oct 23;56:2964-8. Swedish. No abstract available.

PMID:
13799436
45.

[Smoking & lung cancer].

BERGQVIST S.

Sven Lakartidn. 1959 Jun 26;56(26):1843-51. Swedish. No abstract available.

PMID:
13676046
46.

Investigation on the bacterial flora in the bronchi in cases of pulmonary tuberculosis.

BERGQVIST S, HAGERMAN F.

Acta Chir Scand Suppl. 1959;Suppl 245:47-50. No abstract available.

PMID:
13799434
47.

[Changes in incidence of tuberculous pleurisy in Stockholm in the period from 1940 to 1955].

BERGQVIST S, BERLIN SO.

Sven Lakartidn. 1958 Apr 3;55(14):953-62. Swedish. No abstract available.

PMID:
13556596
48.

[Spontaneous pneumothorax & its treatment].

BERGQVIST S.

Sven Lakartidn. 1958 Jan 10;55(2):72-7. Swedish. No abstract available.

PMID:
13529739
49.

The antibody response of the tuberculous guineapig to non-tuberculous antigens.

BERGQVIST S, PACKALEN T.

Acta Pathol Microbiol Scand. 1958;43(1):73-9. No abstract available.

PMID:
13532719
50.

[Variations in incidence & age distribution of acute pleurisy in Stockholm 1940-55].

BERGQVIST S, BERLIN SO.

Nord Med. 1957 Sep 19;58(38):1424-5. Swedish. No abstract available.

PMID:
13484035

Supplemental Content

Loading ...
Support Center